Citations

Clear

2303 citation(s) found for "Yu, Edward".

IPF pathogenesis is dependent upon TGFβ induction of IGF‐1
Hernandez, Danielle M. , Kang, Jeong Han , Choudhury, Malay , Andrianifahanana, Mahefatiana, Yin, Xueqian , Leof, Edward B. , Limper, Andrew H.

Mayo Clinic

The FASEB Journal | February 18, 2020 | Volume: 34 | Issue: 4 | Pages: 5363-5388

10.1096/fj.201901719rr | PMID 32067272 Get It

Abstract Pathogenic fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), have some of the worst prognoses and affect millions of people worldwide. With unclear etiology and minimally effective therapies, two‐thirds of IPF patients die within 2‐5 years from this progressive interstitial lung disease. Transforming Growth Factor Beta (TGFβ) and insulin‐like growth factor‐1 (IGF‐1) are known to promote fibrosis; however, myofibroblast specific upregulation of IGF‐1 in the initiation and progression of TGFβ‐induced fibrogenesis and IPF have remained unexplored. To address this, the current study (1) documents the upregulation of IGF‐1 via TGFβ in myofibroblasts and fibrotic lung tissue, as well as its correlation with decreased pulmonary function in advanced IPF; (2) identifies IGF‐1's C1 promoter as mediating the increase in IGF‐1 transcription by TGFβ in pulmonary fibroblasts; (3) determines that SMAD2 and mTOR signaling are required for TGFβ‐dependent Igf‐1 expression in myofibroblasts; (4) demonstrates IGF‐1R activation is essential to support TGFβ‐driven profibrotic myofibroblast functions and excessive wound healing; and (5) establishes the effectiveness of slowing the progression of murine lung fibrosis with the IGF‐1R inhibitor OSI‐906. These findings expand our knowledge of IGF‐1's role as a novel fibrotic‐switch, bringing us one step closer to understanding the complex biological mechanisms responsible for fibrotic diseases and developing effective therapies.
Mendelian Randomization of Circulating Polyunsaturated Fatty Acids and Colorectal Cancer Risk
Khankari, Nikhil K. , Banbury, Barbara L. , Borges, Maria Carolina , Haycock, Philip , Arndt, Volker , Berndt, Sonja I. , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Conti, David V. , English, Dallas R. , Figueiredo, Jane C. , Giovannucci, Edward L. , Gunter, Marc J. , Hampe, Jochen , Hoffmeister, Michael , Joshi, Amit D. , Lemire, Mathieu , Li, Li , Lindblom, Annika , Martín, Vicente , Moreno, Vı́ctor , Offit, Kenneth, Rennert, Gad , Schafmayer, Clemens , Schmit, Stephanie L. , Slattery, Martha L. , Thibodeau, Stephen N. , Weinstein, Stephanie J. , Win, Aung Ko , Woods, Michael O. , Wu, Anna H. , Murff, Harvey J. , Gruber, Stephen B. , Peters, Ulrike , Brenner, Hermann , Borges, Maria C , Arndt, Volker , Brenner, Hermann , Chang-Claude, Jenny , English, Dallas R , Giles, Graham G , Hoffmeister, Michael , Martín, Vicente , Moreno, Victor , Pharoah, Paul D P , Rennert, Gad , Sakoda, Lori C , Slattery, Martha L , Weinstein, Stephanie J , Win, Aung K , Wolk, Alicja , Denny, Joshua C , Gunter, Marc J , Haycock, Philip , Brenner, Hermann , Hampe, Jochen , Conti, David V , Lindblom, Annika , Albanes, Demetrius , Bezieau, Stéphane , Campbell, Peter T. , Chan, Andrew T. , Cotterchio, Michelle , Giles, Graham G. , Hopper, John L. , Jenkins, Mark A. , Marchand, Loı̈c Le , Li, Christopher I , Newcomb, Polly A. , Pharoah, Paul D.P. , Sakoda, Lori C. , Song, Mingyang , Ulrich, Cornelia M. , White, Emily , Wolk, Alicja , Cai, Qiuyin , Denny, Joshua C. , Edwards, Todd L. , Zheng, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 12, 2020 | Volume: 29 | Issue: 4 | Pages: 860-870

10.1158/1055-9965.epi-19-0891 | PMID 32051193 Get It

Abstract Background: Results from epidemiologic studies examining polyunsaturated fatty acids (PUFA) and colorectal cancer risk are inconsistent. Mendelian randomization may strengthen causal inference from observational studies. Given their shared metabolic pathway, examining the combined effects of aspirin/NSAID use with PUFAs could help elucidate an association between PUFAs and colorectal cancer risk. Methods: Information was leveraged from genome-wide association studies (GWAS) regarding PUFA-associated SNPs to create weighted genetic scores (wGS) representing genetically predicted circulating blood PUFAs for 11,016 non-Hispanic white colorectal cancer cases and 13,732 controls in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). Associations per SD increase in the wGS were estimated using unconditional logistic regression. Interactions between PUFA wGSs and aspirin/NSAID use on colorectal cancer risk were also examined. Results: Modest colorectal cancer risk reductions were observed per SD increase in circulating linoleic acid [ORLA = 0.96; 95% confidence interval (CI) = 0.93–0.98; P = 5.2 × 10−4] and α-linolenic acid (ORALA = 0.95; 95% CI = 0.92–0.97; P = 5.4 × 10−5), whereas modest increased risks were observed for arachidonic (ORAA = 1.06; 95% CI = 1.03–1.08; P = 3.3 × 10−5), eicosapentaenoic (OREPA = 1.04; 95% CI = 1.01–1.07; P = 2.5 × 10−3), and docosapentaenoic acids (ORDPA = 1.03; 95% CI = 1.01–1.06; P = 1.2 × 10−2). Each of these effects was stronger among aspirin/NSAID nonusers in the stratified analyses. Conclusions: Our study suggests that higher circulating shorter-chain PUFAs (i.e., LA and ALA) were associated with reduced colorectal cancer risk, whereas longer-chain PUFAs (i.e., AA, EPA, and DPA) were associated with an increased colorectal cancer risk. Impact: The interaction of PUFAs with aspirin/NSAID use indicates a shared colorectal cancer inflammatory pathway. Future research should continue to improve PUFA genetic instruments to elucidate the independent effects of PUFAs on colorectal cancer.
Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
LaCasce, Ann S. , Bociek, R. Gregory , Sawas, Ahmed , Agura, Edward, Matous, Jeffrey, Ansell, Stephen M. , Crosswell, Howland E. , Islas‐Ohlmayer, Miguel, Behler, Caroline, Cheung, Eric, Forero‐Torres, Andres , O’Connor, Owen A. , Josephson, Neil C. , Advani, Ranjana H. , Advani, Ranjana H , Caimi, Paolo F. , Vose, Julie M. , Wang, Yinghui

Mayo Clinic

British Journal of Haematology | February 12, 2020 | Volume: 189 | Issue: 3 | Pages: No page available

10.1111/bjh.16499 | PMID 32048731 Get It

Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment
Knox, Molly G., Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal, Belden, Christine M. , Zamrini, Edward , Caviness, John N., Sue, Lucia I., Davis, Kathryn, Dugger, Brittany N. , Beach, Thomas G. , Mehta, Shyamal A, Adler, C H , Dugger, Brittany N , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Serrano, Geidy E. , Sabbagh, Marwan Noel

Mayo Clinic

Movement Disorders | February 8, 2020 | Volume: 35 | Issue: 5 | Pages: 845-850

10.1002/mds.27991 | PMID 32034933 Get It

AbstractObjectiveThere are few neuropathological studies on Parkinson's disease with mild cognitive impairment (PD‐MCI). Those published reveal coexisting Lewy body and Alzheimer's disease pathology. Our objective is to determine the pathology that underlies PD‐MCI.MethodsWe used data from the Arizona Study of Aging and Neurodegenerative Disorders, a longitudinal clinicopathological study. Of 736 autopsied subjects with standardized movement and cognitive assessments, 25 had PD‐MCI. Neuropathological findings, including Lewy body and Alzheimer's disease pathology, were compared in PD subjects with amnestic MCI (A‐MCI) and nonamnestic MCI (NA‐MCI).ResultsSignificant pathological heterogeneity within PD‐MCI was found. This included varying Lewy body stages, Alzheimer's disease pathology, and cerebral amyloid angiopathy. There was a significant increase in the severity of Lewy body pathology (meeting The Unified Staging System for Lewy Body disorders neocortical stage) in nonamnestic MCI (7/1, 63%) when compared with amnestic MCI (3/14, 21%, P = 0.032).ConclusionAlthough a small study, distinct pathological changes may contribute to PD‐MCI phenotype. © 2020 International Parkinson and Movement Disorder Society
Circadian and multiday seizure periodicities, and seizure clusters in canine epilepsy
Gregg, Nicholas M. , Nasseri, Mona , Křemen, Václav , Patterson, Edward E., Sturges, Beverly K., Denison, Timothy J, Brinkmann, Benjamin H. , Worrell, Gregory A. , Brinkmann, Benjamin H , Kremen, Vaclav , Worrell, Gregory A , Gregg, Nicholas M , Denison, Timothy J

Mayo Clinic

Brain Communications | February 6, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaa008 | PMID 32161910 Get It

Abstract Advances in ambulatory intracranial EEG devices have enabled objective analyses of circadian and multiday seizure periodicities, and seizure clusters in humans. This study characterizes circadian and multiday seizure periodicities, and seizure clusters in dogs with naturally occurring focal epilepsy, and considers the implications of an animal model for the study of seizure risk patterns, seizure forecasting and personalized treatment protocols. In this retrospective cohort study, 16 dogs were continuously monitored with ambulatory intracranial EEG devices designed for humans. Detailed medication records were kept for all dogs. Seizure periodicity was evaluated with circular statistics methods. Circular non-uniformity was assessed for circadian, 7-day and approximately monthly periods. The Rayleigh test was used to assess statistical significance, with correction for multiple comparisons. Seizure clusters were evaluated with Fano factor (index of dispersion) measurements, and compared to a Poisson distribution. Relationships between interseizure interval (ISI) and seizure duration were evaluated. Six dogs met the inclusion criteria of having at least 30 seizures and were monitored for an average of 65 weeks. Three dogs had seizures with circadian seizure periodicity, one dog had a 7-day periodicity, and two dogs had approximately monthly periodicity. Four dogs had seizure clusters and significantly elevated Fano factor values. There were subject-specific differences in the dynamics of ISI and seizure durations, both within and between lead and clustered seizure categories. Our findings show that seizure timing in dogs with naturally occurring epilepsy is not random, and that circadian and multiday seizure periodicities, and seizure clusters are common. Circadian, 7-day, and monthly seizure periodicities occur independent of antiseizure medication dosing, and these patterns likely reflect endogenous rhythms of seizure risk.
Endoscopic Endonasal Orbital Surgery
Glicksman, Jeffrey, Peris‐Celda, Maria , Kenning, Tyler, Pinheiro‐Neto, Carlos , Pinheiro-Neto, Carlos D , Wladis, Edward J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 5, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1702447 Get It

Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention
Latif, Faisal , Uyeda, Lauren , Edson, Robert , Bhatt, Deepak L. , Goldman, Steven , Holmes, David R. , Shunk, Kendrick , Aggarwal, Kul, Bolad, Islam, Ziada, Khaled M. , McFalls, Edward O. , Irimpen, Anand, Truong, Huu Tam, Kinlay, Scott , Velagaleti, Raghava S. , Rangan, Bavana V. , Mavromatis, Kreton , Shih, Mei-Chiung , Ziada, Khaled , Bhatt, Deepak L , Rao, Sunil V. , Uretsky, Barry F. , Papademetriou, Vasilios , Banerjee, Subhash , Brilakis, Emmanouil S.

Mayo Clinic

Circulation: Cardiovascular Interventions | February 5, 2020 | Volume: 13 | Issue: 2 | Pages: No page available

10.1161/circinterventions.119.008494 | PMID 32019343 Get It

Background: Direct stenting without pre-dilation or post-dilation has been advocated for saphenous vein graft percutaneous coronary intervention to decrease the incidence of distal embolization, periprocedural myocardial infarction, and target lesion revascularization. Methods: We performed a post hoc analysis of patients enrolled in the DIVA (Drug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT 01121224) prospective, double-blind, randomized controlled trial. Patients were stratified into stent-only and balloon-stent groups. Primary end point was 12-month incidence of target vessel failure (defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization). Secondary end points included all-cause death, stent thrombosis, myocardial infarction, and target lesion revascularization during follow-up. Results: Of the 575 patients included in this substudy, 185 (32%) patients underwent stent-only percutaneous coronary intervention. Patients in the stent-only versus balloon-stent group had similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% versus 19%; hazard ratio, 1.34 [95% CI, 0.86–2.08]; P =0.19). During long-term follow-up (median of 2.7 years), the incidence of definite stent thrombosis (1% versus 5%; hazard ratio, 9.20 [95% CI, 1.23–68.92]; P =0.0085), the composite of definite or probable stent thrombosis (5% versus 11%; hazard ratio, 2.52 [95% CI, 1.23–5.18]; P =0.009), and target vessel myocardial infarction (8% versus 14%; hazard ratio, 1.92 [95% CI, 1.08–3.40]; P =0.023) was lower in the stent-only group. Multivariable analysis showed that a higher number of years since coronary artery bypass grafting and >1 target saphenous vein graft lesions were associated with increased target vessel failure during entire follow-up, while preintervention Thrombolysis in Myocardial Infarction-3 flow was protective. Conclusions: In patients undergoing percutaneous coronary intervention of de novo saphenous vein graft lesions, there was no difference in target vessel failure at 12 months and long-term follow-up in the stent-only versus the balloon-stent group; however, the incidence of stent thrombosis was lower in the stent-only group, as was target vessel myocardial infarction. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT 01121224.
The Diabetes Technology Society Green Diabetes Initiative
Klonoff, David C. , Thompson, Bithika , Kerr, David , Han, Julia , Krisiunas, Edward , Cook, Curtiss B. , Thompson, Bithika M, Heinemann, Lutz

Mayo Clinic

Journal of Diabetes Science and Technology | February 5, 2020 | Volume: 14 | Issue: 3 | Pages: 507-512

10.1177/1932296820904175 | PMID 32019344 Get It

History and evolution of regional anesthesiology and acute pain medicine fellowship training
Shapiro, David , Hargett, Mary J. , Neal, Joseph M. , Mariano, Edward R. , Liguori, Gregory A., Shapiro, David Michael , Mariano, Edward R , Kopp, Sandra L.

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 30, 2020 | Volume: 45 | Issue: 4 | Pages: 311-314

10.1136/rapm-2019-100915 | PMID 32001624 Get It

Introduction In 2016, individual training programs in regional anesthesiology and acute pain medicine (RA/APM) became eligible for accreditation by the Accreditation Council for Graduate Medical Education (ACGME), thereby culminating a process that began 15 years earlier. Herein, we review the origins of regional anesthesia training in the USA, the events leading up to accreditation and the current state of the fellowship. Methods We reviewed pertinent literature on the historical aspects of RA/APM in the USA, related subspecialty training and the formation and current state of RA/APM fellowship training programs. Additionally, a survey was distributed to the directors of the 74 RA/APM fellowships that existed as of 1 January 2017 to gather up-to-date, program-specific information. Results The survey yielded a 76% response rate. Mayo Clinic Rochester and Virginia Mason Medical Center likely had the first structured RA/APM fellowships with formalized curriculums and stated objectives, both starting in 1982. Most programs (86%), including ACGME and non-ACGME fellowships, came into existence after the year 2000. Six responding programs have or previously had RA/APM comingled with another subspecialty. Eight current programs originally offered unofficial or part-time fellowships in RA/APM, with fellows also practicing as attending physicians. Discussion The history of RA/APM training in the USA is a tortuous one. It began with short ‘apprenticeships’ under the tutelage of the early proponents of regional anesthesia and continues today with 84 official RA/APM programs and a robust fellowship directors’ group. RA/APM programs teach skills essential to the practice and improvement of anesthesiology as a specialty.